U.S. Biologics Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. biologics market highlights
- The U.S. biologics market generated a revenue of USD 238,697.1 million in 2025 and is expected to reach USD 501,971.3 million by 2033.
- The U.S. market is expected to grow at a CAGR of 9.7% from 2026 to 2033.
- In terms of segment, microbial was the largest revenue generating source in 2025.
- Mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2025 | USD 238,697.1 million |
| Market revenue in 2033 | USD 501,971.3 million |
| Growth rate | 9.7% (CAGR from 2026 to 2033) |
| Largest segment | Microbial |
| Fastest growing segment | Mammalian |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.1% of the global biologics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. biologics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 83,486.3 million by 2033.
The U.S market for biologics accounted for the significant share in 2017 owing to rising R&D spending for biologic development coupled with the presence of a large number of FDA-approved drugs in the country.
The U.S. is hosting a large number of biologics pipelines in various stages of development. More than 900 biological molecules are under clinical investigation in the country. Steady growth in the number of new biological approvals in the country is anticipated to boost revenue generation for the U.S. market of biologics.
In 2015, 13 new therapeutic biologics were approved. In 2014, 10 top-selling biologics of U.S.-based companies such as Amgen and Biogen accounted for USD 73 billion with respect to revenue generation. Moreover, AbbVie’s HUMIRA is estimated to generate the highest revenue with USD 12.5 billion in sales.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
U.S. Biologics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.01% in 2025.
Horizon Databook has segmented the U.S. biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S market for biologics accounted for the significant share in 2017 owing to rising R&D spending for biologic development coupled with the presence of a large number of FDA-approved drugs in the country.
The U.S. is hosting a large number of biologics pipelines in various stages of development. More than 900 biological molecules are under clinical investigation in the country. Steady growth in the number of new biological approvals in the country is anticipated to boost revenue generation for the U.S. market of biologics.
In 2015, 13 new therapeutic biologics were approved. In 2014, 10 top-selling biologics of U.S.-based companies such as Amgen and Biogen accounted for USD 73 billion with respect to revenue generation. Moreover, AbbVie’s HUMIRA is estimated to generate the highest revenue with USD 12.5 billion in sales.
- U.S. Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
- Microbial
- Mammalian
- Others
- U.S. Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- U.S. Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
- U.S. Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Outsourced
Reasons to subscribe to Biologics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
- Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Biologics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Biologics Market, 2021-2033 (US$M)
US Source - Biologics Market Statistics, 2025 - 2033 (US$M)
Related industry reports
No Records
No related reports found.
Related statistics
No Records
No related statistics found.